Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 0.72 |
| ▸ | DRD2 | P14416 | 9/20 | 0.72 |
| ▸ | DRD4 | P21917 | 8/20 | 0.72 |
| ▸ | DRD3 | P35462 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156990 | 0.87 | GRM2 (0.81) | GRM2DRD2DRD4DRD3LMNA | |
| SCHEMBL14374007 | 0.84 | GRM2 (0.72) | GRM2DRD2DRD4DRD3LMNA | |
| SCHEMBL4147514 | 0.84 | GRM2 (1.00) | GRM2DRD2DRD4DRD3 | |
| SCHEMBL4139937 | 0.82 | GRM2 (0.70) | GRM2DRD2DRD4DRD3LMNA | |
| SCHEMBL12629355 | 0.82 | GRM2 (0.67) | GRM2DRD2DRD4DRD3LMNA | |
| SCHEMBL14197759 | 0.82 | GRM2 (0.67) | GRM2DRD2DRD4DRD3LMNA | |
| SCHEMBL4146825 | 0.82 | GRM2 (0.70) | GRM2DRD2DRD4DRD3LMNA | |
| SCHEMBL4144202 | 0.81 | GRM2 (0.65) | GRM2DRD2DRD4DRD3LMNA | |
| SCHEMBL15730124 | 0.80 | GRM2 (0.71) | GRM2DRD2DRD4DRD3LMNA | |
| SCHEMBL6585574 | 0.80 | GRM2 (0.67) | GRM2DRD2DRD4DRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | GRM2 4477/4885DRD2 2308/4885DRD4 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.